A yearly monitoring system that followed current Great Clinical Practice recommendations was run routinely. Ethical Issues Palivizumab is registered but not reimbursed in the Netherlands for preterm infants born in a gestational age group of 33 to 35 weeks. Because RSV immunoprophylaxis works well in stopping RSV lower respiratory tract illness in such preterm infants,18 our research was marked as a therapeutic study. The institutional review board at the University INFIRMARY Utrecht determined that the 50 percent potential for benefit of RSV prevention with palivizumab outweighed the risk of moderate unwanted effects due to the intramuscular administration of placebo and the responsibility of participating in this trial.Gloria Steele, the agency’s acting assistant administrator, said that Us citizens could be proud that tens of an incredible number of kids are alive and healthful because their taxes dollars were wisely and compassionately used abroad. She added, The challenge now could be to build on these successes to save lots of the remaining millions of kids who are dying needlessly . This article is definitely republished with kind permission from our close friends at The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Policy Survey, search the archives, or join email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is released for Kaisernetwork.org, a free of charge service of The Henry J.